Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $22.60 Consensus PT from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $22.60.

Several research firms have issued reports on TBPH. HC Wainwright upped their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen lowered shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. B. Riley Financial reissued a “neutral” rating and set a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. BTIG Research lowered their price objective on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of TBPH. Quarry LP purchased a new stake in Theravance Biopharma during the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd boosted its position in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC grew its stake in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the period. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma News Summary

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: HC Wainwright sharply raised FY‑2026 and quarterly EPS forecasts and keeps a Buy rating and $27 target, signaling materially improved earnings expectations that could support a rebound. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Zacks highlights the stock as deeply oversold after a ~30% four‑week decline and notes analyst upward estimate revisions, arguing the pullback may be a buying opportunity for a technical reversal. Zacks: Buy the dip
• Neutral Sentiment: Market context: TBPH is trading with above‑average volume, inside its 1‑year range ($7.90–$21.03) and below the 50‑day moving average — a mixed technical picture that increases sensitivity to news flow.
• Negative Sentiment: Theravance reported a late‑stage drug trial failure that prompted a sharp share decline and workforce reductions, a material fundamental negative that reduces near‑term upside. Share tumbles and jobs to go after Theravance failure
• Negative Sentiment: Management is reportedly considering a possible sale after the trial setback, which introduces strategic uncertainty and potential valuation pressure while options are explored. MSN: Possible sale after trial setback
• Negative Sentiment: Oppenheimer downgraded TBPH from Outperform to Market Perform, signaling reduced near‑term conviction from a major bank and likely contributing to selling pressure. Oppenheimer downgrades Theravance
• Negative Sentiment: BTIG issued a pessimistic forecast for the stock, adding to negative analyst sentiment and raising downside risk until clarity on the pipeline or strategic actions emerges. BTIG pessimistic forecast

Theravance Biopharma Price Performance

TBPH stock opened at $13.57 on Friday. The stock has a market capitalization of $687.59 million, a P/E ratio of 23.81 and a beta of 0.17. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The business has a fifty day moving average price of $18.95 and a 200-day moving average price of $16.88.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.